Brief: Oryzon Gets U.S. Patent Grant For Vafidemstat In Borderline Personality Disorder
08/07/2026 07:07
BRIEF-Oryzon Gets U.S. Patent Grant For Vafidemstat In Borderline Personality Disorder July 8 (Reuters) - Oryzon Genomics SA ORY.MC:
ANNOUNCES U.S. PATENT GRANT FOR VAFIDEMSTAT IN BORDERLINE PERSONALITY DISORDER (BPD)
U.S. PATENT TO EXPIRE IN MARCH 2043, INCLUDING 1,095 DAYS OF PATENT TERM ADJUSTMENT
NOTICE OF ALLOWANCE ALSO RECEIVED IN A CORRESPONDING CANADIAN PATENT APPLICATION
Further company coverage: ORY.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 567 69 66 00;))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28